Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling

摘要

The present invention is based on a novel, alternatively spliced human isoform of MD-2 (MD-2s). In addition, the present invention relates to modified MD-2 proteins, wherein one or more tyrosine residues have been mutated to phenylalanine. In various embodiments, the invention relates to methods and kits for preventing, reducing the likelihood of developing and/or treating various conditions using MD-2s. The invention also describes methods of determining the risk of a subject to various conditions.

主权项

1. A method of inhibiting lipopolysaccharide (“LPS”) induced lung inflammation in a subject in need thereof, comprising:
providing a purified polypeptide comprising an amino acid sequence that is at least 85% identical to SEQ ID NO:1 or SEQ ID NO:2; and administering the polypeptide to the subject to inhibit LPS induced lung inflammation.